Amplia opens new front in ovarian cancer fight
Amplia Therapeutics has finalised plans for its PRROSE phase two ovarian cancer trial, with site activation and patient recruitment targeted before year-end.
We haven't written up this one. The Age has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.